• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The perils of surrogate endpoints.替代终点的风险。
Eur Heart J. 2015 Sep 1;36(33):2212-8. doi: 10.1093/eurheartj/ehv164. Epub 2015 May 13.
2
[Update diabetes mellitus and cardiovascular diseases].[糖尿病与心血管疾病的更新内容]
MMW Fortschr Med. 2012 Apr 19;154(7):95-8.
3
Influence of serum cholesterol and cholesterol subfractions on restenosis following successful coronary intervention.
Semin Interv Cardiol. 1999 Sep;4(3):111-9. doi: 10.1053/siic.1999.0098.
4
Therapy and clinical trials: beyond low-density lipoprotein cholesterol reduction.治疗与临床试验：超越低密度脂蛋白胆固醇降低
Curr Opin Lipidol. 2006 Dec;17(6):708-12. doi: 10.1097/MOL.0b013e328010a049.
5
[Lipid metabolism disorder: detection and treatment. 5: Treatment of hyperlipidemia in manifest coronary heart disease, diabetes mellitus and hypertension. National cholesterol initiative].
Fortschr Med. 1991 Jun 10;109(17):361-3.
6
Management of diabetes in cardiovascular patients: diabetic heart disease.心血管疾病患者的糖尿病管理：糖尿病性心脏病
Heart. 2008 Mar;94(3):369-75. doi: 10.1136/hrt.2006.098210.
7
Recent trials of lipid lowering.近期降脂试验
Int J Clin Pract. 2007 Jul;61(7):1145-59. doi: 10.1111/j.1742-1241.2007.01425.x.
8
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.针对残余心血管风险：提高高密度脂蛋白胆固醇水平。
Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401.
9
Cardiovascular complications of renal disease.肾脏疾病的心血管并发症
Heart. 2001 Oct;86(4):459-66. doi: 10.1136/heart.86.4.459.
10
The ADVANCE trial: further PROGRESS with HOPE.
J Hum Hypertens. 2007 Dec;21(12):911-3. doi: 10.1038/sj.jhh.1002300. Epub 2007 Oct 25.

引用本文的文献

1
Era of surrogate endpoints and accelerated approvals: a comprehensive review on applicability, uncertainties, and challenges from regulatory, payer, and patient perspectives.替代终点与加速批准时代：从监管、支付方和患者角度对适用性、不确定性及挑战的全面综述
Eur J Clin Pharmacol. 2025 May;81(5):605-623. doi: 10.1007/s00228-025-03822-w. Epub 2025 Mar 13.
2
Regulatory, Translational, and Operational Considerations for the Incorporation of Biomarkers in Drug Development.药物研发中生物标志物纳入的监管、转化及操作考量
Ther Innov Regul Sci. 2025 May;59(3):519-526. doi: 10.1007/s43441-025-00763-5. Epub 2025 Mar 8.
3
Outcome data for renal denervation: craving the unattainable?肾去神经术的结果数据：渴望无法实现之事？
Hypertens Res. 2024 Oct;47(10):2773-2775. doi: 10.1038/s41440-024-01667-x. Epub 2024 Apr 15.
4
Does renal denervation require cardiovascular outcome-driven data?肾去神经术是否需要心血管结局驱动的数据？
Hypertens Res. 2024 Oct;47(10):2633-2643. doi: 10.1038/s41440-024-01598-7. Epub 2024 Mar 11.
5
Invasive Versus Conservative Management of NSTEMI Patients Aged ≥ 75 Years: Commentary.≥75岁非ST段抬高型心肌梗死患者的侵入性治疗与保守治疗：述评
Arq Bras Cardiol. 2024 Mar 4;120(12):e20230364. doi: 10.36660/abc.20230364. eCollection 2024.
6
From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology.从识别到治疗：神经退行性疾病病理学中生物标志物的意义。
Int J Mol Sci. 2023 Nov 9;24(22):16119. doi: 10.3390/ijms242216119.
7
Bridging Treatment Implementation Gaps in Patients With Heart Failure: JACC Focus Seminar 2/3.心力衰竭患者治疗实施差距的弥合：JACC 焦点研讨会 2/3.
J Am Coll Cardiol. 2023 Aug 8;82(6):544-558. doi: 10.1016/j.jacc.2023.05.050.
8
Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs.2016 - 19年新抗生素监管批准时的证据及成本：对美国食品药品监督管理局批准药物的队列研究
BMJ Med. 2022 Dec 12;1(1):e000227. doi: 10.1136/bmjmed-2022-000227. eCollection 2022.
9
Association Between Work Status and the Use of Healthcare Services Among Women in the Republic of Korea.韩国女性的工作状况与医疗服务利用之间的关联
Saf Health Work. 2022 Mar;13(1):51-58. doi: 10.1016/j.shaw.2021.10.004. Epub 2021 Nov 1.
10
Efficacy End Points and Dose Analysis of Food and Drug Administration-Approved Novel Drugs in 2020.2020年美国食品药品监督管理局批准的新型药物的疗效终点和剂量分析
Curr Ther Res Clin Exp. 2022 Jul 1;97:100680. doi: 10.1016/j.curtheres.2022.100680. eCollection 2022.

本文引用的文献

1
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.依洛尤单抗降低血脂和心血管事件的疗效和安全性。
N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.
2
Progression of coronary artery calcification seems to be inevitable, but predictable - results of the Heinz Nixdorf Recall (HNR) study.冠状动脉钙化的进展似乎不可避免，但可预测——海因茨·尼克斯多夫召回（HNR）研究结果。
Eur Heart J. 2014 Nov 7;35(42):2960-71. doi: 10.1093/eurheartj/ehu288. Epub 2014 Jul 25.
3
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.美国心脏病学会/美国心脏协会 2013 年成人治疗血胆固醇以降低动脉粥样硬化性心血管疾病风险指南：好的、坏的和不确定的：与 2011 年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南的比较。
Eur Heart J. 2014 Apr;35(15):960-8. doi: 10.1093/eurheartj/ehu107. Epub 2014 Mar 17.
4
High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target.高密度脂蛋白：血管保护作用、功能障碍及作为治疗靶点的潜力。
Circ Res. 2014 Jan 3;114(1):171-82. doi: 10.1161/CIRCRESAHA.114.300935.
5
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).2014 年成人高血压管理的循证指南：第八届联合国家委员会（JNC 8）任命的专家组报告。
JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.
6
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南：美国心脏病学会/美国心脏协会实践指南工作组报告
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12.
7
The bumpy road to evidence: why many research findings are lost in translation.通往证据的崎岖之路：为何许多研究成果在转化过程中迷失
Eur Heart J. 2013 Nov;34(43):3329-35. doi: 10.1093/eurheartj/eht396. Epub 2013 Oct 2.
8
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.阿格列汀治疗 2 型糖尿病合并急性冠脉综合征患者。
N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.
9
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.沙格列汀与 2 型糖尿病患者的心血管结局。
N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.
10
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.2 型糖尿病强化生活方式干预的心血管效应。
N Engl J Med. 2013 Jul 11;369(2):145-54. doi: 10.1056/NEJMoa1212914. Epub 2013 Jun 24.

The perils of surrogate endpoints.

作者信息

Weintraub William S, Lüscher Thomas F, Pocock Stuart

机构信息

Cardiology Section, Christiana Care Health System, 4755 Ogletown-Stanton Road, Newark, DE 19317, USA

Department of Cardiology, University Heart Center, University of Zurich, Zurich, Switzerland.

出版信息

Eur Heart J. 2015 Sep 1;36(33):2212-8. doi: 10.1093/eurheartj/ehv164. Epub 2015 May 13.

DOI:10.1093/eurheartj/ehv164
PMID:25975658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4554958/
Abstract
摘要